IGF2 and lysosomal storage disease: A follow-up study by the same group confirmed that LV-IGF2.GAAco nearly normalized the skeletal muscle proteome in preclinical Pompe disease model without inducing off-target effects, reinforcing the therapeutic potential of codon-optimized LVs for lysosomal disorders [80].